Bu Xiang Pharmaceutical: Cancellation of wholly-owned subsidiary Shanxi Bu Xiang Medical Research Institute.

Boehringer Ingelheim announced that, in order to optimize resource allocation and organizational structure, reduce management costs, the company has decided to cancel its wholly-owned subsidiary Shaanxi Boehringer Pharmaceuticals Research Institute. The subsidiary was established on October 18, 2019, with a registered capital of 8 million yuan. The company held 100% of its equity, but it has not yet conducted any actual business activities. The cancellation does not involve related party transactions or major asset restructuring, and does not require approval from the board of directors or shareholders' meeting, and it has been completed. This cancellation will not have a significant adverse impact on the company's consolidated financial statements, overall business, and profitability.